Undisclosed AKT inhibitor / Totus Medicines - LARVOL DELTA

Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly (GlobeNewswire) - "Totus Medicines...announced today it has entered into a multi-target research collaboration with Eli Lilly and Company to discover small molecule drug candidates against undisclosed targets...Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to generate high-quality covalent compounds against Lilly targets. Subsequently, Lilly and Totus will have options to exclusively pursue preclinical and clinical development and commercialization of compounds identified from the collaboration and receive milestone payments....'This collaboration validates our strategy of using our platform to generate drug candidates for partners as well as our own pipeline, which consists of a covalent PI3Kα inhibitor in Phase 1 and an AKT covalent inhibitor in preclinical development.'"

Licensing / partnership • Oncology • Solid Tumor